Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates
Precision targeting is a hot topic in cancer nanomedicine, as conventional chemotherapies cause systemic toxicities, creating an urgent need for more selective treatments. Although antibody-drug conjugates (ADCs) are the current gold standard in targeted therapy, their clinical performance remains limited. As an alternative, we previously developed a multivalent protein nanocarrier (T22-GFP-H6) displaying the CXCR4-targeting peptide T22, which offers super-selective tumor accumulation driven by CXCR4 overexpression. This innovative nanovehicle showed favorable biodistribution for targeted delivery of antitumor drugs, including monomethyl auristatin E (MMAE), in a first-generation stochastic nanoconjugate format. However, unlike ADCs, where conjugation strategy is known to influence pharmacokinetics and efficacy, these parameters remain largely unexplored in non-antibody multivalent nanocarriers. Here, we evaluated the impact of precise payload accommodation using two site-specific strategies that attach a single MMAE molecule at distinct structural sites, and we compared them with first-generation nanoconjugates. The conjugation strategy substantially affected the biodistribution and antitumor efficacy, with a solvent-exposed cysteine-conjugation distal to the targeting ligand proving most effective. At equimolar nanocarrier dosing, this construct achieved tumor control similar to the stochastic conjugate in a disseminated hematologic malignancy despite an approximately 4-fold lower MMAE load (drug-to-protein ratio, DPR = 1 vs DPR ≈ 4). Moreover, at equimolar MMAE dosing, it clearly outperformed both the stochastic conjugate and the alternative site-directed design. These findings align with trends in advanced ADCs and provide practical design rules for rational, site-specific conjugation in next-generation protein-based nanomedicines aimed at enabling dose-sparing in oncology.
Proyecto:
Instituto de Salud Carlos III PI20/00400
,
Instituto de Salud Carlos III PI23/00318
,
Instituto de Salud Carlos III PI21/00150
,
Instituto de Salud Carlos III PI24/01476
,
Instituto de Salud Carlos III PI24/00012
,
Agencia Estatal de Investigación PDC2022-133858-I00
,
Agencia Estatal de Investigación CNS2024-154280
,
Generalitat de Catalunya 2021/SGR-01140
,
Generalitat de Catalunya 2021/SGR-00092
,
Instituto de Salud Carlos III CB06/01/1031
,
Ministerio de Sanidad y Consumo CB06/01/0014
,
Ministerio de Sanidad y Consumo CB06/01/0019
,
Instituto de Salud Carlos III CB06/07/0011
,
Instituto de Salud Carlos III CP19/00028
,
Instituto de Salud Carlos III CP24/00111
,
Instituto de Salud Carlos III FI21/00012
,
"la Caixa" Foundation 12070029